SCHEMBL2269403

SCHEMBL2269403

O=c1ccn(-c2ccccc2)nc1Cc1cccc(O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.47
ADORA2A P29274 2/20 0.46
ADORA1 P30542 2/20 0.46
ADORA3 P0DMS8 1/20 0.46
ALDH1A1 P00352 2/20 0.43
GAA P10253 1/20 0.42
POLB P06746 1/20 0.41
ELOVL1 Q9BW60 1/20 0.41
IDH1 O75874 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ADORA2B P29275 1/20 0.39
HTT P42858 2/20 0.39
KDM4E B2RXH2 1/20 0.39
TP53 P04637 1/20 0.39
CYP2D6 P10635 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PARP1 P09874 2/20 0.39
NR1H3 Q13133 2/20 0.39
DRD2 P14416 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13506827 0.84 CYP2C9 (0.43) CYP2C9ADORA3ALDH1A1GAAPOLB
SCHEMBL13505244 0.84 GAA (0.45) CYP2C9ALDH1A1GAAPOLBELOVL1
SCHEMBL2223282 0.84 CYP2C9 (0.43) CYP2C9ADORA2AADORA1ADORA3ALDH1A1
SCHEMBL13505233 0.83 MEN1 (0.41) CYP2C9ALDH1A1POLBELOVL1MEN1
SCHEMBL13274891 0.82 ELOVL1 (0.45) CYP2C9ALDH1A1GAAPOLBELOVL1
SCHEMBL12518021 0.80 CYP2C9 (0.40) CYP2C9ALDH1A1GAAPOLBELOVL1
SCHEMBL2220139 0.80 PARP1 (0.53) CYP2C9ALDH1A1GAAELOVL1MEN1
SCHEMBL2222072 0.80 MEN1 (0.39) CYP2C9ALDH1A1GAAPOLBIDH1
SCHEMBL2264421 0.78 HRH3 (0.46) CYP2C9ALDH1A1POLBHTT
SCHEMBL2220117 0.78 CYP2C9 (0.41) CYP2C9ALDH1A1GAAPOLBELOVL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2515657-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-10-31 EP disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
US-20120264735-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2012-10-18 US disclosed
WO-2011084402-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264735-A1 TYROSINE KINASE INHIBITORS ABL1, MET, ERBB2 CYP2C9 4808/4885ADORA2A 2646/4885ADORA1 3440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.